Table 2.

AD Onset and Characteristics

Patient	AD (n)	AD Events	WHO Classificationa	TET Diagnosis to First AD (mo)b	AD Treatments
1	6	CASPR2 encephalitis; Good syndrome; enteropathy; minimal change disease; MG; Sweet syndrome	Type B	N/A	Azathioprine, cyclophosphamide, cyclosporine, daratumumab, everolimus, IVIG, plasmapheresis, rituximab, steroids, tacrolimus
2	1	MG	Type B	N/A	IVIG, mycophenolate, pyridostigmine, steroids
3	1	MG	Type B	84	None
4	2	Good syndrome; MG	Type B	N/A	Azathioprine, pyridostigmine, plasmapheresis
5	1	Neuropathy	Type B	N/A	IVIG, steroids
6	1	MG	Type B	N/A	Pyridostigmine
7	3	Amegakaryocytic thrombocytopenia; arthritis; PRCA	Type B	160	Steroids
8	1	MG	Type AB	1	None
9	1	PRCA	Type AB	39	Steroids
10	1	PRCA	Thymoma, NOS	172	Steroids
11	2	Enteropathy, neutropenia	Thymoma, NOS	47	Everolimus, octreotide, steroids
12	1	PRCA	Thymoma, NOS	168	None
13	3	Dermatomyositis, pemphigus vulgaris, MG	Thymoma, NOS	N/A	Mycophenolate, pyridostigmine, steroids
14	1	PRCA	TC	30	Cyclosporine, IVIG, steroids
15	1	ITP	TC	30	Steroids
16	2	Arthritis; Good syndrome	Thymic neoplasm	184	IVIG, methotrexate, steroids

AD, autoimmune disease; ITP, immune thrombocytopenic purpura; IVIG, intravenous immune globulin; MG, myasthenia gravis; N/A, not applicable; NOS, not otherwise specified; PRCA, pure red cell aplasia; TC, thymic carcinoma; TET, thymic epithelial tumor.

^aThymoma listed as type A, type B, or type AB.

^bCases where AD preceded TET diagnosis, including those with multiple ADs if at least one AD occurred before TET diagnosis, were designated as N/A.